CL2017002354A1 - Compuestos derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd. - Google Patents
Compuestos derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd.Info
- Publication number
- CL2017002354A1 CL2017002354A1 CL2017002354A CL2017002354A CL2017002354A1 CL 2017002354 A1 CL2017002354 A1 CL 2017002354A1 CL 2017002354 A CL2017002354 A CL 2017002354A CL 2017002354 A CL2017002354 A CL 2017002354A CL 2017002354 A1 CL2017002354 A1 CL 2017002354A1
- Authority
- CL
- Chile
- Prior art keywords
- activity
- compounds derived
- bicyclic heteroaryls
- phd inhibitors
- heteroaryls fused
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1504565.1A GB201504565D0 (en) | 2015-03-18 | 2015-03-18 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017002354A1 true CL2017002354A1 (es) | 2018-05-04 |
Family
ID=53051992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017002354A CL2017002354A1 (es) | 2015-03-18 | 2017-09-15 | Compuestos derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd. |
Country Status (31)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE049305T2 (hu) | 2016-02-24 | 2020-09-28 | Pfizer | Pirazolo[1,5-a]pirazin-4-il származékok mint JAK-inhibitorok |
| US11254668B2 (en) | 2017-08-14 | 2022-02-22 | Pfizer Inc. | Pyrazolo[1,5-A]pyrazin-4-yl and related derivatives |
| ES3016010T3 (en) * | 2018-09-13 | 2025-05-08 | Kissei Pharmaceutical | Imidazopyridinone compound |
| CN110950806A (zh) * | 2019-11-14 | 2020-04-03 | 安庆博曼生物技术有限公司 | 四乙基氯化铵催化嘧啶环羟基氯代制备方法 |
| JP7504822B2 (ja) * | 2020-03-12 | 2024-06-24 | キッセイ薬品工業株式会社 | イミダゾピリジノン化合物を含む医薬組成物 |
| US11718622B2 (en) | 2020-03-16 | 2023-08-08 | Exelixis Inc. | Heterocyclic adenosine receptor antagonists |
| EP4122928A4 (en) * | 2020-04-20 | 2023-12-13 | Shenzhen TargetRx, Inc. | SOLID FORM OF PYRAZINE SUBSTITUTED NICOTINAMIDE AND PRODUCTION AND USE THEREOF |
| JP7654071B2 (ja) * | 2020-10-20 | 2025-03-31 | アムジエン・インコーポレーテツド | 複素環スピロ化合物及び使用方法 |
| US12492178B2 (en) | 2021-09-01 | 2025-12-09 | Empathbio, Inc. | Stable polymorph of R-MDMA HCl |
| JP2024541910A (ja) | 2021-10-28 | 2024-11-13 | インシリコ メディシン アイピー リミテッド | プロリルヒドロキシラーゼドメイン含有タンパク質（ｐｈｄ）阻害剤およびその使用方法 |
| JP2025500892A (ja) * | 2021-12-17 | 2025-01-15 | アケビア セラピューティクス インコーポレイテッド | 選択的ｐｈｄ１阻害剤化合物、組成物、及び使用方法 |
| US11912680B2 (en) | 2021-12-28 | 2024-02-27 | Empathbio, Inc. | Nitric oxide releasing prodrugs of MDA and MDMA |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4209621A (en) | 1979-04-27 | 1980-06-24 | American Cyanamid Company | (Substituted-phenyl)-1,2,4-triazolo[4,3-a]-pyrimidines and (substituted-phenyl)-1,2,4-triazolo[1,5-a]pyrimidines |
| US4572910A (en) * | 1983-03-03 | 1986-02-25 | Riker Laboratories, Inc. | Triazolo[1,5-c]pyrimidines substituted by nitrogen-containing heterocyclic rings |
| DK135184A (da) * | 1983-03-03 | 1984-10-10 | Riker Laboratories Inc | Triazol(4,3-c)- og triazol(1,5-c)pyrimidiner |
| PL360027A1 (en) | 2000-06-30 | 2004-09-06 | Wyeth | Substituted-triazolopyrimidines as anticancer agents |
| JP2010065026A (ja) | 2008-08-13 | 2010-03-25 | Ishihara Sangyo Kaisha Ltd | ピリジル−トリアゾロピリミジン誘導体又はその塩、並びにそれらを含有する有害生物防除剤 |
| JP2010065024A (ja) | 2008-08-14 | 2010-03-25 | Ishihara Sangyo Kaisha Ltd | トリアゾロピリミジン誘導体又はその塩を含有する有害生物防除剤 |
| HRP20140705T1 (hr) * | 2009-07-17 | 2014-09-12 | Japan Tobacco, Inc. | Spoj triazolopiridina i njegovo djelovanje kao inhibitora prolil hidroksilaze i induktora proizvodnje eritropoetina |
| JP2011168582A (ja) * | 2010-01-21 | 2011-09-01 | Ishihara Sangyo Kaisha Ltd | トリアゾロピリジン誘導体又はその塩、それらの製造方法及びそれらを含有する有害生物防除剤 |
| JPWO2014030716A1 (ja) * | 2012-08-23 | 2016-08-08 | 田辺三菱製薬株式会社 | ピラゾロピリミジン化合物 |
-
2015
- 2015-03-18 GB GBGB1504565.1A patent/GB201504565D0/en not_active Ceased
-
2016
- 2016-03-17 UA UAA201708877A patent/UA123668C2/uk unknown
- 2016-03-17 AU AU2016234209A patent/AU2016234209B2/en active Active
- 2016-03-17 SG SG11201707280VA patent/SG11201707280VA/en unknown
- 2016-03-17 PH PH1/2017/501699A patent/PH12017501699B1/en unknown
- 2016-03-17 ES ES16715122T patent/ES2774052T3/es active Active
- 2016-03-17 EP EP16715122.4A patent/EP3271357B1/en active Active
- 2016-03-17 CN CN201680022416.0A patent/CN107531698B/zh active Active
- 2016-03-17 WO PCT/JP2016/059782 patent/WO2016148306A1/en not_active Ceased
- 2016-03-17 JP JP2017549107A patent/JP6726681B2/ja active Active
- 2016-03-17 MX MX2017011902A patent/MX2017011902A/es active IP Right Grant
- 2016-03-17 DK DK16715122.4T patent/DK3271357T3/da active
- 2016-03-17 EA EA201792057A patent/EA035739B1/ru unknown
- 2016-03-17 CR CR20170468A patent/CR20170468A/es unknown
- 2016-03-17 HU HUE16715122A patent/HUE047918T2/hu unknown
- 2016-03-17 CA CA2979024A patent/CA2979024C/en active Active
- 2016-03-17 TN TNP/2017/000384A patent/TN2017000384A1/en unknown
- 2016-03-17 PT PT167151224T patent/PT3271357T/pt unknown
- 2016-03-17 BR BR112017019653-0A patent/BR112017019653B1/pt active IP Right Grant
- 2016-03-17 KR KR1020177030091A patent/KR102609431B1/ko active Active
- 2016-03-17 GE GEAP201614608A patent/GEP20207095B/en unknown
- 2016-03-17 MY MYPI2017703420A patent/MY194873A/en unknown
- 2016-03-17 PE PE2018000126A patent/PE20180656A1/es unknown
- 2016-03-17 NZ NZ735631A patent/NZ735631A/en unknown
- 2016-03-17 US US15/558,824 patent/US10287286B2/en active Active
-
2017
- 2017-09-03 IL IL254277A patent/IL254277B/en active IP Right Grant
- 2017-09-14 CO CONC2017/0009353A patent/CO2017009353A2/es unknown
- 2017-09-15 CL CL2017002354A patent/CL2017002354A1/es unknown
- 2017-09-18 DO DO2017000209A patent/DOP2017000209A/es unknown
- 2017-10-02 ZA ZA2017/06612A patent/ZA201706612B/en unknown
- 2017-10-18 EC ECIEPI201769696A patent/ECSP17069696A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017002354A1 (es) | Compuestos derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd. | |
| SV2018005794A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| CR20150371A (es) | Inhibidores de prmt5 y sus usos | |
| SV2017005514A (es) | Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos | |
| MX2018003432A (es) | Compuestos heterociclicos y usos de los mismos. | |
| MX2020011449A (es) | Oxiesteroles y metodos de uso de los mismos. | |
| ECSP16074478A (es) | Compuestos novedosos | |
| MX381707B (es) | Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen. | |
| BR112017013491A2 (pt) | compostos de pirimidina fundida para o tratamento de hiv | |
| CL2016001287A1 (es) | Benzamidas sustituidas y procedimiento para su uso | |
| MX2017013886A (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa. | |
| MX2015012062A (es) | Inhibidores de jak2 y alk2 y metodos para su uso. | |
| CU20180073A7 (es) | Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| NI201400107A (es) | Compuestos de heterociclilo como inhibidores de mek | |
| CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
| UY37288A (es) | Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| DOP2014000036A (es) | Compuestos de piridazinona y su uso como inhibidores daao | |
| UY35535A (es) | ?Derivados de fenil sulfonamidas?. | |
| UY35708A (es) | Compuestos novedosos como antagonistas del receptor de ácido lisofosfatidico | |
| CO2019002523A2 (es) | Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica | |
| CL2017002498A1 (es) | Piridopirimidinonas y su uso como modulares del receptor nmda | |
| CU20180028A7 (es) | DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, ÚTILES COMO INHIBIDORES DUALES DE DYRK1/CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN | |
| UY35536A (es) | ?derivados de sulfonamida?. | |
| ECSP16074482A (es) | Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina | |
| ECSP18056196A (es) | Derivados de indano |